Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Recruiting
Merck Sharp & Dohme Corp.
Phase 2
2019-01-11
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Recruiting
Amy C. Sherman, MD
Phase 2
2019-01-11
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Recruiting
Dana-Farber Cancer Institute
Phase 2
2019-01-11
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
Recruiting
National Cancer Institute (NCI)
Phase 2
2019-10-07
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus
(CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a
virus that may be carried for life and does not cause illness in most healthy individuals.
However, in people whose immune systems are lowered (such as those undergoing stem cell
transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is
made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes)
placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce
immunity (the ability to recognize and respond to an infection) and reduce the risk of
developing complications related to CMV infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
